Clinical trial · Observational
Validation of Clinical Biomarkers Using Spatial Transcriptomics and Development of a Diagnostic Test to Characterize the Progression Potential of Cutaneous Precancerous Lesions
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Actinic keratoses are precancerous skin lesions that are the most common among all cancers and precancerous conditions in fair-skinned populations. The distinctive feature of these actinic keratoses is that some progress into skin cancers known as cutaneous carcinomas, while others regress spontaneously; currently, there is no way to distinguish between them, either through clinical observation or biological methods. The goal of the Diagno-KA project is to develop a diagnostic test that would distinguish between actinic keratoses that progress to cancer-so they can be surgically removed early (before they become severe and metastasize)-and those that regress, thereby avoiding unnecessary surgical intervention (to prevent scarring).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diagnostic | — | UNRESOLVED | — |
| Skin Cancer | Malignant Skin Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Biomarker validation
- timeFrame
- Until the end of the study on average 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with skin carcinomas and actinic keratoses Exclusion Criteria: * minor patient
References
Publications (0)
Data not yet available